Rectal Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Colorectal Cancer (1222)

Colon Cancer (153)

Colorectal Adenocarcinoma (8)

Colorectal Cancer (1222)

Colon Cancer (153)

Colorectal Adenocarcinoma (8)

›

HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	trastuzumab + tucatinib Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) trastuzumab + tucatinib Sensitive : A2 NCCN - 2wk	trastuzumab + tucatinib Sensitive: A2 - Guideline NCCN - 2 weeks trastuzumab + tucatinib Sensitive : A2 NCCN - 2 weeks - (New A2)
HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) fam-trastuzumab deruxtecan-nxki Sensitive : A2 NCCN - 2wk	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline NCCN - 2 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	bevacizumab-adcd Sensitive: A1 - Approval bevacizumab-adcd Sensitive : A1	bevacizumab-adcd Sensitive: A1 - Approval bevacizumab-adcd Sensitive : A1
MSI-H/dMMR	Rectal Cancer	MSI-H/dMMR	Rectal Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	FOLFIRINOX Sensitive: A2 - Guideline FOLFIRINOX Sensitive : A2	FOLFIRINOX Sensitive: A2 - Guideline FOLFIRINOX Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2
MSI-H/dMMR	Rectal Cancer	MSI-H/dMMR	Rectal Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
MSI-H/dMMR	Rectal Cancer	MSI-H/dMMR	Rectal Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	trifluridine/tipiracil Sensitive: A2 - Guideline trifluridine / tipiracil Sensitive : A2	trifluridine/tipiracil Sensitive: A2 - Guideline trifluridine / tipiracil Sensitive : A2
HER-2 amplification	Rectal Cancer	HER-2 amplification	Rectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2
NTRK3 fusion	Rectal Cancer	NTRK3 fusion	Rectal Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Rectal Cancer	NTRK2 fusion	Rectal Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Rectal Cancer	NTRK1 fusion	Rectal Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Rectal Cancer	NTRK1 fusion	Rectal Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Rectal Cancer	NTRK2 fusion	Rectal Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Rectal Cancer	NTRK3 fusion	Rectal Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
BRAF V600	Rectal Cancer	BRAF V600	Rectal Cancer	cetuximab + encorafenib Sensitive: A2 - Guideline cetuximab + encorafenib Sensitive : A2	cetuximab + encorafenib Sensitive: A2 - Guideline cetuximab + encorafenib Sensitive : A2
BRAF V600	Rectal Cancer	BRAF V600	Rectal Cancer	panitumumab + encorafenib Sensitive: A2 - Guideline panitumumab + encorafenib Sensitive : A2	panitumumab + encorafenib Sensitive: A2 - Guideline panitumumab + encorafenib Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	ziv-aflibercept IV Sensitive: A2 - Guideline ziv-aflibercept IV Sensitive : A2	ziv-aflibercept IV Sensitive: A2 - Guideline ziv-aflibercept IV Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	5-fluorouracil + leucovorin calcium Sensitive: A2 - Guideline 5-fluorouracil + leucovorin calcium Sensitive : A2	5-fluorouracil + leucovorin calcium Sensitive: A2 - Guideline 5-fluorouracil + leucovorin calcium Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	mFOLFOX6 Sensitive: A2 - Guideline mFOLFOX6 Sensitive : A2	mFOLFOX6 Sensitive: A2 - Guideline mFOLFOX6 Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
KRAS wild-type	Rectal Cancer	KRAS wild-type	Rectal Cancer	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	mFOLFOX7 Sensitive: A2 - Guideline mFOLFOX7 Sensitive : A2	mFOLFOX7 Sensitive: A2 - Guideline mFOLFOX7 Sensitive : A2
NRAS wild-type	Rectal Cancer	NRAS wild-type	Rectal Cancer	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2

Rectal Cancer

Associations(67)

Associations
(67)